All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

CV Sciences Q3 revenue falls 7% amid regulatory pressure

By Reuters News


Overview

  • US hemp wellness firm's Q3 revenue fell 7% yr/yr amid regulatory headwinds

  • Company achieved positive adjusted EBITDA, reversing losses from prior year and previous quarter

  • Operating income turned positive, helped by lower expenses and a legal settlement gain


Outlook

  • Company continues to monitor potential restrictive federal regulations set for December 11, 2026

  • CV Sciences plans to focus on brand strength and expansion into broader wellness categories


Result Drivers

  • REGULATORY PRESSURE - Co said lower sales volumes and average prices were due to restrictive federal and state regulations

  • NEW PRODUCTS - 48% of Q3 net revenue came from products launched since January 2023, reflecting increased contribution from recent launches


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

$3.03 mln

Q3 Net Loss

$93,000

Q3 Gross Profit

$1.51 mln

Q3 Operating Expenses

$1.14 mln

Q3 Operating Income

$377,000

Q3 Pretax Loss

$93,000


Reuters Recommended Reads

  • Nov 10 - Hims & Hers to offer peptides as soon as November after US eases curbs

  • Nov 12 - Health Canada warns after bacteria found in unauthorized peptides

  • Nov 10 - Corbus Pharmaceuticals Q3 net loss widens on higher expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.